All Stories

  1. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study
  2. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report
  3. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia
  4. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis
  5. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients
  6. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis
  7. Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply
  8. Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease
  9. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up
  10. Ma2 antibody‐associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory
  11. Autoimmune encephalitis: what the radiologist needs to know
  12. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers
  13. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
  14. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
  15. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review
  16. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages
  17. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword
  18. Alzheimer’s disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era
  19. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome
  20. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
  21. Sex differences in brain atrophy in dementia with Lewy bodies
  22. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer’s disease
  23. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases
  24. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease
  25. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
  26. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment
  27. Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit?
  28. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB)
  29. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements
  30. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy
  31. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
  32. Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder
  33. A case of Huntington disease‐like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era
  34. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease
  35. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
  36. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
  37. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy
  38. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
  39. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
  40. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses
  41. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort
  42. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
  43. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia
  44. Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI)
  45. Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease
  46. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson’s Disease
  47. Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
  48. Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature
  49. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
  50. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection
  51. Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease
  52. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
  53. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration
  54. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
  55. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)
  56. Sex differences in neuroimaging biomarkers in healthy subjects and dementia
  57. Rapid eye movement sleep behavior disorder: A proof‐of‐concept neuroprotection study for prodromal synucleinopathies
  58. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools
  59. Neuroimaging Findings in Mild Cognitive Impairment
  60. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease
  61. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease
  62. Utility of quantitative EEG in early Lewy body disease
  63. Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy
  64. Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression
  65. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study
  66. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study
  67. The fate of patients with REM sleep behavior disorder and mild cognitive impairment
  68. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia
  69. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years
  70. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
  71. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study
  72. Serum neurofilament light chain rate of change in Alzheimer’s disease: potentials applications and notes of caution
  73. Could arterial spin labelling perfusion imaging uncover the invisible in N ‐methyl‐ d ‐aspartate receptor encephalitis?
  74. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI
  75. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease
  76. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease
  77. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study
  78. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders
  79. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  80. Getting the high school diploma with only one hemisphere: a case report
  81. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
  82. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier
  83. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers
  84. Clinical utility and research frontiers of neuroimaging in movement disorders